Answers are grounded in this paper and cite their sources.
Multimodal bioimaging probes merging optical imaging, magnetic resonance imaging (MRI), and X-ray computed tomography (CT) capabilities have attracted considerable attention due to their potential biomedical applications. Lanthanide-based nanoparticles are promising candidates for multimodal imaging because of their optical, magnetic and X-ray attenuation properties. We prepared a set of hexagonal-phase (β)-NaGdF₄:Yb,Er/NaGdF₄/NaDyF₄ core/shell/shell nanoparticles (Dy-CSS NPs) and demonstrated their optical/T₂-weighted MRI/CT multimodal capabilities. A known drawback of multimodal probes that merge the upconverting Er³⁺/Yb³⁺ ion pair with magnetic Dy³⁺ ions for T₂-weighted MRI is the loss of upconversion (UC) emission due to Dy³⁺ poisoning. Particular attention was paid to controlled nanoparticle architectures with tuned inner shell thicknesses separating Dy³⁺ and Er³⁺/Yb³⁺ to shed light on the distance-dependent loss of UC due to Yb³⁺ → Dy³⁺ energy transfer. Based on the Er³⁺ UC spectra and the excited state lifetime of Yb³⁺, a 4 nm thick NaGdF₄ inner shell did not only restore but enhanced the UC emission. We further investigated the effect of the outer NaDyF₄ shell thickness on the particles' magnetic and CT performance. MRI T₂ relaxivity measurements in vitro at a magnetic field of 7 T performed on citrate-capped Dy-CSS NPs revealed that NPs with the thickest outer shell thickness (4 nm) exhibited the highest r₂ value, with a superior T₂ contrast effect compared to commercial iron oxide and other Dy-based T₂ contrast agents. In addition, the citrate-capped Dy-CSS NPs were demonstrated suitable for CT in in vitro imaging phantoms at X-ray energies of 110 keV, rendering them interesting alternatives to clinically used iodine-based agents that operate at lower energies.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: